13.53
0.32 (2.42%)
| Penutupan Terdahulu | 13.21 |
| Jumlah Dagangan | 2,139,450 |
| Harga / Jualan (P/S) | 11.15 |
| Harga / Buku (P/B) | 2.13 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -2.49 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.25% |
| Nisbah Semasa (MRQ) | 21.47 |
| Aliran Tunai Operasi (OCF TTM) | -39.28 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.34 M |
| Pulangan Atas Aset (ROA TTM) | -22.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Contineum Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.75 |
|
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.82% |
| % Dimiliki oleh Institusi | 79.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Johnson & Johnson | 30 Jun 2026 | 1,979,173 |
| Balyasny Asset Management L.P. | 30 Jun 2026 | 1,522,793 |
| Longaeva Partners L.P. | 30 Jun 2026 | 812,757 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| STENGONE CARMINE N. | - | 15.94 | -2,500 | -39,850 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,500 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -39,850 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 15.94 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| STENGONE CARMINE N. | Pegawai | 08 Sep 2026 | Jual automatik (-) | 2,500 | 15.94 | 39,850 |
| STENGONE CARMINE N. | Pegawai | 08 Sep 2026 | Pelaksanaan pilihan | 2,500 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |